Abstract: A self-assembled therapeutic dendron-micelle includes a first amphiphilic dendron-coil, a second amphiphilic dendron-coil, and optionally a third amphiphilic dendron-coil, and an encapsulated BRD4 ligand or BRD4 proteolysis targeting chimera. The first and optional third amphiphilic dendron-coils have a therapeutic peptide conjugated thereto. Also included are pharmaceutical compositions containing the dendron-micelles, methods of making the dendron-micelles, and therapeutic methods including administering the dendron-micelles to a subject in need thereof.

Abstract: Certain embodiments are directed to methods of using BRD4 inhibitors for treating IgE-mediated diseases.

Abstract: Certain embodiments are directed to methods of using BRD4 inhibitors for treating IgE-mediated diseases.

Abstract: Certain embodiments are directed to methods of treating chronic lung diseases in a subject comprising administering to a subject diagnosed with, exhibiting symptoms of, or at risk of developing a chronic lung disease a therapeutically effective amount of a BRD4 inhibitor or a CDK9 inhibitor to the subject.

Abstract: The present invention provides compositions and methods for detecting, analyzing, and identifying biomolecules used to diagnose patient with risk of DHF. More particularly, the invention provides plasma biomarkers including complement factor D to complement factor H (FactorD/FactorH) ratio and levels of one or more of IL2, desmoplakin, and high molecular weight albumin, which are used to detect risk of developing DHF.

Abstract: Certain embodiments include methods for assessing a subject having a trypanosome infection for the presence or absence of indications of cardiomyopathy.

Abstract: Certain embodiments are directed to methods of treating chronic lung diseases in a subject comprising administering to a subject diagnosed with, exhibiting symptoms of, or at risk of developing a chronic lung disease a therapeutically effective amount of a BRD4 inhibitor or a CDK9 inhibitor to the subject.

Abstract: The present invention provides compositions and methods for detecting, analyzing, and identifying biomolecules used to diagnose patient with risk of DHF. More particularly, the invention provides plasma biomarkers including complement factor D to complement factor H (FactorD/FactorH) ratio and levels of one or more of IL2, desmoplakin, and high molecular weight albumin, which are used to detect risk of developing DHF.

Abstract: The present invention provides methods for detecting, analyzing, and identifying biomolecules used to identifying patient with dengue-like symptom who are at risk of DHF. The inventive method comprises detecting in a sample from a subject dengue infected patient one or more biomarkers selected from the group consisting of IL-10, fibrinogen, C4A, immunoglobulin, tropomyosin, and three isoforms of albumin, and which are used in a predictive MARS model to detect patients with risk of developing DHF.

Abstract: The present invention provides methods for detecting, analyzing, and identifying biomolecules used to identifying patient with dengue-like symptom who are at risk of DHF. The inventive method comprises detecting in a sample from a subject dengue infected patient one or more biomarkers selected from the group consisting of IL-10, fibrinogen, C4A, immunoglobulin, tropomyosin, and three isoforms of albumin, and which are used in a predictive MARS model to detect patients with risk of developing DHF.

Abstract: The present invention provides methods for detecting, analyzing, and identifying biomolecules used to identifying patient with dengue-like symptom who are at risk of DHF. The inventive method comprises detecting in a sample from a subject dengue infected patient one or more biomarkers selected from the group consisting of IL-10, fibrinogen, C4A, immunoglobulin, tropomyosin, and three isoforms of albumin, and which are used in a predictive MARS model to detect patients with risk of developing DHF.